Business
Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
DURHAM, N.C., May 14, 2025--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced the strategic prioritization and acceleration of PBGENE-DMD, the Company’s first-in-class in vivo gene editing approach for Duchenne Muscular Dystrophy (DMD) and highlighted a PBGENE-DMD poster presentation at the American Society of Gene and Cell T
About this update from Precision Biosciences, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/22954b2e34198e3fffefccf946daa0b2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/U1obUnQxtxE0KrvNFl4ffQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/22954b2e34198e3fffefccf946daa0b2","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/g4q56jKXBVJagf2wexrvOg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/22954b2e34198e3fffefccf946daa0b2","width":1024,"height":512}},"lazy":false},{"type":"text","content":"- PBGENE-DMD is a first-in-class in vivo gene editing approach for the majority of Duchenne Muscular Dystrophy patients impacted by dystrophin mutations in the most common ‘hot spot’ region between exons 45-55 -","length":211,"tagName":"p","attribs":{}},{"type":"text","content":"- Final clinical candidate PBGENE-DMD demonstrates compelling preclinical data for durably improving functional benefit over time -","length":131,"tagName":"p","attribs":{}},{"type":"text","content":"- Precision targeting to submit an Investigational New Drug (IND) and/or Clinical Trial Application (CTA) for PBGENE-DMD in 2025 with clinical data expected in 2026 -","length":166,"tagName":"p","attribs":{}},{"type":"text","content":"- Precision to host a webcast and conference call on Thursday, May 15, 2025 at 8:00 AM ET -","length":91,"tagName":"p","attribs":{}},{"type":"text","content":"DURHAM, N.C., May 14, 2025--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced the strategic prioritization and acceleration of PBGENE-DMD, the Company’s first-in-class in vivo gene editing approach for Duchenne Muscular Dystrophy (DMD) and highlighted a PBGENE-DMD poster presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting being held May 13-17, 2025, in New Orleans, Louisiana.","length":601,"tagName":"p"},{"type":"text","content":""Nomination and acceleration of PBGENE-DMD as our second wholly owned program is a result ...